CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
Natalizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02176031
NCT02176031Phase 2Completed
CompareCT.gov

Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract

Dana-Farber Cancer Institute·interventional·Posted Jun 26, 2014·Updated Apr 17, 2020

In Brief

A Phase 2 clinical trial evaluating Natalizumab and Methylprednisolone for Graft Versus Host Disease. Completed, enrolled 21 participants across 2 sites.

Detailed Summary

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug Natalizumab in treating Acute Graft-Versus-Host Disease (GVHD) in the Gastrointestinal (GI) Tract.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraft Versus Host Disease
CountriesUnited States
CollaboratorsBiogen

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 26, 2014
Enrollment StartJan 1, 2015
Primary CompletionFeb 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 12.0 years ago

Interventions

Natalizumabdrug

Methylprednisolonedrug